Perrigo Banks On New Products To Continue Market Share Growth
This article was originally published in The Tan Sheet
Perrigo got a sales boost in its latest quarter due to Leiner's absence from the U.S. OTC market, but the Allegan, Mich.-based firm looks to new product launches to continue its sales growth as its chief private-label competitor gears up to reenter the market
You may also be interested in...
Adams Respiratory Therapeutics has been hit with another patent claim challenge involving its Mucinex line as it prepares to launch line extensions for its blockbuster brand and other new products in time for the cough/cold season
Heightened concerns over product quality triggered by adulterated Chinese imports and the need for more than one U.S. private-label supplier are fueling Leiner Health Products' optimism as it prepares to reenter the OTC market and recover from setbacks that led to a $27.5 million net loss in its latest quarter, CEO Robert Kaminski said Aug. 14
The U.S. District Court for the Southern District of New York invalidated a key patent for Johnson & Johnson/Merck's Pepcid Complete, opening the door for Perrigo to enter the market with a private-label equivalent